CERo Therapeutics, Inc. develops a cellular immunotherapy platform that integrates the anti-tumor functions of both innate and adaptive immune systems into a single T cell. This technology aims to enhance tumor cell clearance for the treatment of hematologic malignancies and solid tumors.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail to fully eradicate tumors, and can lack the ability to stimulate a comprehensive immune response, limiting long-term efficacy. Existing immunotherapies may not effectively integrate both innate and adaptive immune system components for optimal tumor cell clearance.
Solution
CERo Therapeutics is developing a cellular immunotherapy platform designed to enhance tumor cell clearance by integrating the anti-tumor functions of both the innate and adaptive immune systems into a single T cell. This approach aims to provide a more complete and durable response against hematologic malignancies and solid tumors. The CER T-cell platform offers novel approaches by exploiting natural immune processes to target and eliminate cancer cells. By combining multiple forms of tumor clearance, the platform seeks to overcome the limitations of current treatment options and improve patient outcomes.
Target Audience
The primary target audience includes patients with hematologic malignancies and solid tumors, as well as clinicians and researchers in the field of oncology seeking more effective and durable cancer therapies.
Features
- CER T-cells integrate the capabilities of both innate and adaptive immune systems.
- The platform is designed for potential application in both hematologic malignancies and solid tumors.
- CER-1236 is the lead compound currently in Phase 1 clinical trials for Acute Myeloid Leukemia.
- The company holds multiple U.S. patents and a European patent application allowance related to its lead compound.